{"id":4369,"date":"2026-11-17T09:00:00","date_gmt":"2026-11-17T13:00:00","guid":{"rendered":"https:\/\/www.insilens.com\/?p=4369"},"modified":"2026-11-17T20:44:40","modified_gmt":"2026-11-18T00:44:40","slug":"fda-grants-neladalkib-accelerated-approval","status":"publish","type":"post","link":"https:\/\/www.insilens.com\/?p=4369","title":{"rendered":"FDA Grants Neladalkib Accelerated Approval"},"content":{"rendered":"<p><img fetchpriority=\"high\" decoding=\"async\" width=\"768\" height=\"432\" src=\"https:\/\/www.insilens.com\/wp-content\/uploads\/2026\/11\/20261117_Nuvalent_Neladalkib_Therapeutic_Indications-768x432.png\" alt=\"\" class=\"attachment-medium_large size-medium_large wp-image-4374\" srcset=\"https:\/\/www.insilens.com\/wp-content\/uploads\/2026\/11\/20261117_Nuvalent_Neladalkib_Therapeutic_Indications-768x432.png 768w, https:\/\/www.insilens.com\/wp-content\/uploads\/2026\/11\/20261117_Nuvalent_Neladalkib_Therapeutic_Indications-300x169.png 300w, https:\/\/www.insilens.com\/wp-content\/uploads\/2026\/11\/20261117_Nuvalent_Neladalkib_Therapeutic_Indications-1024x576.png 1024w, https:\/\/www.insilens.com\/wp-content\/uploads\/2026\/11\/20261117_Nuvalent_Neladalkib_Therapeutic_Indications-1536x864.png 1536w, https:\/\/www.insilens.com\/wp-content\/uploads\/2026\/11\/20261117_Nuvalent_Neladalkib_Therapeutic_Indications.png 1672w\" sizes=\"(max-width: 768px) 100vw, 768px\" \/><\/p>\n<p><strong>Company<\/strong><\/p>\n<p>Nuvalent<\/p>\n<p><strong>Event Type<\/strong><\/p>\n<p>FDA accelerated approval<\/p>\n<p><strong>Modality<\/strong><\/p>\n<p>Small molecule kinase inhibitor<\/p>\n<p><strong>Asset<\/strong><\/p>\n<p>Neladalkib<\/p>\n<p><strong>Target<\/strong><\/p>\n<p>ALK<\/p>\n<p><strong>Disease Area<\/strong><\/p>\n<p>ALK-positive non-small cell lung cancer<\/p>\n<h4>Summary<\/h4>\n<p>FDA granted accelerated approval to oral ALK inhibitor neladalkib for specified previously treated ALK-positive advanced NSCLC. In ALKOVE-1, confirmed response was 49% among 67 post-alectinib patients and 32% among 155 patients previously exposed to at least two ALK inhibitors and platinum chemotherapy.<\/p>\n<p>The single-arm, multicohort trial used blinded central response review. Among responders, 12-month duration-of-response rates were 52% and 51% in the respective cohorts. FDA lists warnings for hepatic, renal, ocular and creatine-kinase toxicity; dose is 150 mg daily. The action occurred ten days before the previously stated Nov 27 target date.<\/p>\n<h4>Deep Analysis<\/h4>\n<p><strong>Interpretation A:<\/strong> activity after multiple ALK inhibitors supports a useful molecularly selected salvage option, with durability signals.<\/p>\n<p><strong>Interpretation B:<\/strong> cross-trial comparisons cannot show superiority to lorlatinib or other sequencing; response and duration are surrogate endpoints and accelerated approval requires confirmatory benefit. Mutation spectrum, CNS response, resistance and toxicity-driven discontinuation determine displacement. The narrow post-alectinib and heavily pretreated populations should not be generalized to first line.<\/p>\n<h4>Company and Product Background<\/h4>\n<p>ALK-positive NSCLC is driven by oncogenic ALK fusions. Neladalkib is an oral ALK kinase inhibitor designed to suppress resistant ALK signaling after prior targeted therapy.<\/p>\n<h4>Signal Extraction<\/h4>\n<ul>\n<li>FDA primary approval and cohort data verified.<\/li>\n<li>Missing: mature survival, intracranial detail and comparative sequencing outcomes.<\/li>\n<li>Upgrade: confirmatory randomized clinical benefit and robust CNS activity.<\/li>\n<li>Downgrade: resistance or organ toxicity that limits durable exposure.<\/li>\n<\/ul>\n<h4>InSilens Take<\/h4>\n<p>This expands the approved ALK salvage toolkit; it does not establish comparative superiority or verified survival gain.<\/p>\n<h4>Signal Assessment<\/h4>\n<p>Signal Importance: 4 of 5. Signal Direction: positive. Confidence in Facts: High. Confidence in Interpretation: Moderate.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>FDA granted accelerated approval to oral ALK inhibitor neladalkib for specified previously treated ALK-positive advanced NSCLC. In ALKOVE-1, confirmed response was 49% among 67 post-alectinib patients and 32% among 155 patients previously exposed to&#8230;<\/p>\n","protected":false},"author":1,"featured_media":4374,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[3],"tags":[1521,1520,86],"class_list":["post-4369","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-therapeutic-indication","tag-alk-positive-nsclc","tag-neladalkib","tag-nuvalent"],"blocksy_meta":[],"_links":{"self":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts\/4369","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=4369"}],"version-history":[{"count":1,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts\/4369\/revisions"}],"predecessor-version":[{"id":4385,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts\/4369\/revisions\/4385"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/media\/4374"}],"wp:attachment":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=4369"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=4369"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=4369"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}